The front-line therapy for CLL young and fit patients is chemo-immunotherapy with fludarabine-cyclophosphamide-rituximab (FCR). FCR regimen results in a significant myelosuppression and high rates of early and late infections especially in elderly patients. German CLL study group compared FCR vs. bendamustine-rituximab (BR) in fit untreated patients. The response rates with BR or FCR were comparable, BR could be an alternative 1st-line treatment for elderly patients. Here we report retrospective data of 70 elderly (≥65 years) CLL patients from 12 Italian centers treated with BR as front-line therapy. The primary end points were overall response rate (complete remission/partial remission) and safety. Forty-seven males and 23 females, with a median age of 72 years, were included in the study. Eight patients were unfit for CIRS. The OR rate was 88.6% (31.4% CR and 57.2% PR). Progression free survival, treatment free survival and overall survival rates at 2-years were 79%, 90.3% and 89.6%, respectively. Only del17 was independent unfavorable parameter on the response rate and PFS. Our results indicate that BR front-line at standard dose provides a high response rate with a good safety profile, even if more than 50% of patients experienced a bendamustine dose reduction until 70 mg/m2.

Laurenti, L., Innocenti, I., Autore, F., Vannata, B., Efremov, D., Ciolli, S., et al. (2015). Bendamustine in combination with rituximab for elderly patients with previously untreated B-cell chronic lymphocytic leukemia: A retrospective analysis of real-life practice in Italian hematology departments. LEUKEMIA RESEARCH, 39(10), 1066-1070 [10.1016/j.leukres.2015.07.009].

Bendamustine in combination with rituximab for elderly patients with previously untreated B-cell chronic lymphocytic leukemia: A retrospective analysis of real-life practice in Italian hematology departments

Del Poeta, G;Ghio, F;Cantonetti, M;Del Principe, MI;Sica, S;
2015-10-01

Abstract

The front-line therapy for CLL young and fit patients is chemo-immunotherapy with fludarabine-cyclophosphamide-rituximab (FCR). FCR regimen results in a significant myelosuppression and high rates of early and late infections especially in elderly patients. German CLL study group compared FCR vs. bendamustine-rituximab (BR) in fit untreated patients. The response rates with BR or FCR were comparable, BR could be an alternative 1st-line treatment for elderly patients. Here we report retrospective data of 70 elderly (≥65 years) CLL patients from 12 Italian centers treated with BR as front-line therapy. The primary end points were overall response rate (complete remission/partial remission) and safety. Forty-seven males and 23 females, with a median age of 72 years, were included in the study. Eight patients were unfit for CIRS. The OR rate was 88.6% (31.4% CR and 57.2% PR). Progression free survival, treatment free survival and overall survival rates at 2-years were 79%, 90.3% and 89.6%, respectively. Only del17 was independent unfavorable parameter on the response rate and PFS. Our results indicate that BR front-line at standard dose provides a high response rate with a good safety profile, even if more than 50% of patients experienced a bendamustine dose reduction until 70 mg/m2.
ott-2015
Pubblicato
Rilevanza nazionale
Abstract
Sì, ma tipo non specificato
Settore MED/15 - MALATTIE DEL SANGUE
English
Bendamustine; CLL; Elderly patients; First-line treatment; Rituximab; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Disease-Free Survival; Female; Humans; Italy; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Retrospective Studies; Rituximab
Laurenti, L., Innocenti, I., Autore, F., Vannata, B., Efremov, D., Ciolli, S., et al. (2015). Bendamustine in combination with rituximab for elderly patients with previously untreated B-cell chronic lymphocytic leukemia: A retrospective analysis of real-life practice in Italian hematology departments. LEUKEMIA RESEARCH, 39(10), 1066-1070 [10.1016/j.leukres.2015.07.009].
Laurenti, L; Innocenti, I; Autore, F; Vannata, B; Efremov, D; Ciolli, S; Del Poeta, G; Mauro, F; Cortelezzi, A; Borza, P; Ghio, F; Mondello, P; Murru, R; Gozzetti, A; Cariccio, M; Piccirillo, N; Boncompagni, R; Cantonetti, M; Del Principe, M; Reda, G; Bongarzoni, V; Cervetti, G; Pitini, V; Foa, R; Sica, S; D'Arena, G
Articolo su rivista
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2108/134776
Citazioni
  • ???jsp.display-item.citation.pmc??? 11
  • Scopus 25
  • ???jsp.display-item.citation.isi??? 28
social impact